Your browser doesn't support javascript.
loading
Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
Pan, Jonathan; Ghimire, Sushil; Alpdogan, S Onder; Chapman, Andrew; Carabasi, Matthew; DiMeglio, Martina; Gong, Jerald; Martinez-Outschoorn, Ubaldo; Rose, Lewis; Ramirez, Michael; Wagner, John L; Weiss, Mark; Flomenberg, Neal; Pro, Barbara; Porcu, Pierluigi; Filicko-OHara, Joanne; Gaballa, Sameh.
  • Pan J; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Ghimire S; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Alpdogan SO; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Chapman A; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Carabasi M; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • DiMeglio M; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Gong J; Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Martinez-Outschoorn U; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Rose L; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Ramirez M; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Wagner JL; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Weiss M; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Flomenberg N; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Pro B; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Porcu P; Robert H. Lurie Comprehensive Cancer Center, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Filicko-OHara J; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
  • Gaballa S; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Leuk Lymphoma ; 62(3): 590-597, 2021 03.
Article en En | MEDLINE | ID: mdl-33146052
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica Límite: Humans / Middle aged Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma no Hodgkin / Protocolos de Quimioterapia Combinada Antineoplásica Límite: Humans / Middle aged Idioma: En Año: 2021 Tipo del documento: Article